Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof

US9518034B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9518034-B2
Application numberUS-201414514001-A
CountryUS
Kind codeB2
Filing dateOct 14, 2014
Priority dateOct 14, 2013
Publication dateDec 13, 2016
Grant dateDec 13, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

This invention provides enantioenriched heterocyclic enaminone compounds with quaternary stereogenic centers and novel methods of preparing the compounds. Methods include the method for the preparation of a compound of formula (I): comprising treating a compound of formula (II): with a transition metal catalyst under alkylation conditions.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for the preparation of a compound of formula (I): comprising treating a compound of formula (II): with a transition metal catalyst under alkylation conditions, wherein, as valence and stability permit, R 1 and R 2 are independently hydrogen or optionally substituted alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, or alkynyl; or R 1 and R 2 are taken together to form an optionally substituted heterocyclic ring; R 3 is substituted or unsubstituted hydrogen, alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, alkenyl, alkynyl, or halo; R 4 is hydrogen, halogen, alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, alkenyl, or alkynyl; R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are independently selected for each occurrence from hydrogen, hydroxyl, halogen, nitro, alkyl, alkenyl, alkynyl, cyano, carboxyl, sulfate, amino, alkoxy, alkylamino, alkylthio, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, ether, thioether, ester, amide, thioester, carbonate, carbamate, urea, sulfonate, sulfone, sulfoxide, sulfonamide, acyl, acyloxy, acylamino, aryl, heteroaryl, carbocyclyl, heterocyclyl, aralkyl, arylalkoxy, heteroaralkyl, carbocyclylalkyl, and heterocyclylalkyl; W is CR 13 R 13 , O, S, or NR 14 ; R 13 is selected, independently for each occurrence, from hydrogen, hydroxyl, halogen, nitro, alkyl, alkenyl, alkynyl, cyano, carboxyl, sulfate, amino, alkoxy, alkylamino, alkylthio, hydroxyalkyl, alkoxyalkyl, aminoalkyl, thioalkyl, ether, thioether, ester, amide, thioester, carbonate, carbamate, urea, sulfonate, sulfone, sulfoxide, sulfonamide, acyl, acyloxy, acylamino, aryl, heteroaryl, carbocyclyl, heterocyclyl, aralkyl, arylalkoxy, heteroaralkyl, carbocyclylalkyl, and heterocyclylalkyl; R 14 is independently selected for each occurrence from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkenyl, or alkynyl; wherein R 2 and R 4 may combine with the atoms to which they are attached to form an optionally substituted 4-9 membered heterocyclic ring, R 4 and an occurrence of R 13 may combine with the carbons to which they are attached to form an optionally substituted 3-8 membered ring, R 4 and an occurrence of R 14 may combine with the atoms to which they are attached to form an optionally substituted 4-8 membered heterocyclic ring, two occurrences of R 13 may combine with the carbons to which they are attached to form a 3-8 membered ring, or an occurrence of R 13 and an occurrence of R 14 may combine with the atoms to which they are attached to form an optionally substituted 4-8 membered heterocyclic ring; and n is an integer from 1-4. 2. The method of claim 1 , wherein R 5 ,R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , and R 12 are each independently selected for each occurrence from hydrogen, halogen, cyano, alkyl, alkoxy, alkylthio, amide, amine, aryloxy, and arylalkoxy. 3. The method of claim 1 , wherein R 3 is selected from optionally substituted alkyl, aryl, aralkyl, haloalkyl, and hydroxyalkyl. 4. The method of claim 1 , wherein W at each occurrence is CR 13 R 13 and n is an integer from 1-3;and wherein R 13 is selected, independently for each occurrence, from hydrogen, halogen, cyano, alkyl, alkoxy, alkylthio, amide, amine, aryloxy, and arylalkoxy. 5. The method of claim 1 , wherein R 1 and R 2 taken together form an optionally substituted heterocyclic ring. 6. The method of claim 1 , wherein the transition metal catalyst comprises a transition metal selected from palladium, nickel, and platinum. 7. The method of claim 6 , wherein the transition metal catalyst comprises Pd 2 (dba) 3 or Pd 2 (pmdba) 3 . 8. The method of claim 7 , wherein the transition metal catalyst is used in an amount from about 0.1 mol % to about 20 mol % total palladium relative to the compound of formula (II). 9. The method of claim 1 , wherein the transition metal catalyst further comprises an enantioenriched phosphine ligand. 10. The method of claim 9 , wherein the enantioenriched phosphine ligand is a phosphinooxazoline ligand. 11. The method of claim 10 , wherein the phosphinooxazoline ligand is selected from (S)—(CF 3 ) 3 -tBuPHOX and (S)-tBuPHOX. 12. The method of claim 10 , wherein the ligand is used in an amount selected from 0.25 mol % to about 25 mol % relative to the compound of formula (II). 13. The method of claim 1 , wherein the compound of formula (I) is enantioenriched.

Assignees

Inventors

Classifications

  • with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system · CPC title

  • with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9518034B2 cover?
This invention provides enantioenriched heterocyclic enaminone compounds with quaternary stereogenic centers and novel methods of preparing the compounds. Methods include the method for the preparation of a compound of formula (I): comprising treating a compound of formula (II): with a transition metal catalyst under alkylation conditions.
Who is the assignee on this patent?
California Inst Of Techn
What technology area does this patent fall under?
Primary CPC classification C07D295/116. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).